GRI Bio, Inc. (GRI)
NASDAQ · Manufacturing · Pharmaceutical preparations
GRI price, last 12 months
Key stats
- Previous close
- $2.09
- Open
- $2.07
- Day range
- $1.95 – $2.08
- 52-week range
- $1.36 – $64.12
- Volume
- 53.4K
- Avg volume (20 days)
- 583.9K
- Market cap
- $4.5M
Performance
Technicals and fundamentals
About GRI Bio, Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $4.5M